Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Classement en actions #14772
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Prix de l'action
$16.85
Dernière synchronisation: 2023-07-07
Capitalisation boursière
$393.50M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
CH
Échange VectivBio Holding AG (VECT)

Catégorie

Ratio P/B pour VectivBio Holding AG (VECT)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de VectivBio Holding AG, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour VectivBio Holding AG de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.828 -
US
7.5116 -
NL
3.9942 -
AU
8.2199 -
US
- -
CH